
Keytruda
Productby Merck & Co., Inc.
Heard in 49 episodes across 25 shows since Dec 2025
Keytruda is the brand name for pembrolizumab, a humanized monoclonal antibody and programmed cell death protein 1 (PD-1) immune-checkpoint inhibitor. It is used in cancer immunotherapy for many types of cancer and is administered by slow intravenous injection.
Episodes
This week
Expert statements
Share of the conversation
Mentions of Keytruda per 1,000 mentions of anything, 7-day rolling, across the podcasts PodLume Trends follows.
Show the data
| Day | Share (7-day) | Mentions |
|---|---|---|
| Aug 28 | 0.03‰ | 2 |
| Sep 2 | 0.05‰ | 3 |
| Sep 3 | 0.07‰ | 2 |
| Sep 8 | 0.07‰ | 1 |
| Sep 13 | 0.02‰ | 1 |
| Sep 30 | 0.01‰ | 1 |
| Oct 5 | 0.03‰ | 2 |
| Oct 10 | 0.03‰ | 1 |
| Oct 14 | 0.02‰ | 1 |
| Oct 16 | 0.03‰ | 1 |
| Oct 18 | 0.03‰ | 1 |
| Oct 19 | 0.03‰ | 1 |
| Oct 22 | 0.03‰ | 1 |
| Oct 23 | 0.05‰ | 3 |
| Oct 26 | 0.04‰ | 1 |
| Oct 27 | 0.07‰ | 3 |
| Oct 29 | 0.07‰ | 1 |
| Oct 30 | 0.06‰ | 2 |
| Nov 2 | 0.08‰ | 3 |
| Nov 9 | 0.02‰ | 2 |
| Nov 13 | 0.03‰ | 2 |
| Nov 17 | 0.03‰ | 2 |
| Nov 20 | 0.03‰ | 2 |
Email alert
Email me when Keytruda comes up on a podcast
One email a week at most, with the new episodes that mention Keytruda. Free, no account needed, unsubscribe in one click.
What experts have said about Keytruda
2 statements · 2 positive
Lower-priced copycat versions of Keytruda will become available within a few years.
“in a few years, we're going to have copycat versions of drugs like Keytruda that will be available hopefully at much lower prices”
Open the episode · 419: Assessing Merck and Moderna's mRNA cancer vaccineListen at 5:04
Keytruda is pharma’s best-selling drug, generating over $30 billion annually.
“the best-selling drug in pharma right now is a drug called Keytruda. It's a cancer drug. It sells over $30 billion a year”
Open the episode · A Breakthrough Cancer Vaccine Fueled a Biotech Rally. Can It Last?Listen at 25:31
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.
Episodes
49 episodes featuring Keytruda, newest first
- Nov 20, 2026
Biotech weighs AI disruption against a stronger 2027 deal cycleBiotech HangoutNov 20, 2026 - Nov 17, 2026
Amazon backs AI expansion as NVIDIA leadership risk tests the tradeHalftime ReportNov 17, 2026 - Nov 17, 2026
Biotech bets meet a pivotal FDA succession fightBioCentury This WeekNov 17, 2026 - Nov 13, 2026
NVIDIA turmoil meets Anthropic’s IPO gamble and Moderna’s cancer betMad Money w/ Jim CramerNov 13, 2026 - Nov 9, 2026
Immune therapies can trigger delayed, life-threatening organ damageThe Curbsiders Internal Medicine PodcastNov 9, 2026 - Nov 2, 2026
Amy Burroughs turned biotech uncertainty into negotiating powerTiger SistersNov 2, 2026